Answers are grounded in this paper and cite their sources.
AIMS: Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotype-guided dosing of irinotecan presents an individualized dosing strategy that improves patient safety while maintaining therapeutic efficacy. Nonetheless, little is known about its implementation across Europe. This survey-based study provides an overview of UGT1A1 genotype-guided irinotecan dosing practices across Europe and characterizes how institutional, regulatory and practical barriers affect its broader adoption. METHODS: A 41-question survey assessing implementation, best practices and opinions related to UGT1A1 genotyping was distributed to healthcare professionals identified through professional societies and previous publications on pharmacogenetics or irinotecan, as well as through outreach to medical oncology departments and pharmacogenetic laboratories in Europe. The survey was open for participation for 10 weeks from January to March 2026. RESULTS: Of 345 healthcare professionals invited across 34 European countries, 119 (34%) from 107 centres in 27 countries participated. Respondents included clinicians (N = 40), laboratory experts (N = 34), pharmacologists (N = 33) and researchers (N = 12). Eighteen European countries reported varying extents of UGT1A1 genotyping for irinotecan treatment, with extensive pre-treatment implementation currently present in Italy and the Netherlands. Eight countries reported no testing. The most frequently cited drivers of implementation were the presence of clinical guidelines, reimbursement and test availability. UGT1A1 genotyping panels differed considerably across laboratories. CONCLUSIONS: While UGT1A1 genotype-guided dosing of irinotecan is increasingly being adopted in Europe, broad and uniform implementation is still limited and thus far unevenly distributed. Achieving European implementation of pre-treatment UGT1A1 genotyping for irinotecan will require the development and publication of clinical guidelines, test availability and coverage of genotyping costs.
No takes yet. Share an insight, caveat, or question.
Heersche et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: